

3/3/1 (Item 1 from file: 653)
DIALOG(R) File 653:US Patents Fulltext
(c) format only 2000 The Dialog Corp. All rts. reserv.

01620352

Utility
METHOD OF PREPARING AN AUTOGENOUS VACCINE
[CULTURING PROGENITOR CRYPTOCIDES]

PATENT NO.: 4,692,412
ISSUED: September 08, 1987 (19870908)
INVENTOR(s): Livingston, Virginia W., 8492 Prestwick Dr., LaJolla, CA
(California), US (United States of America), 92037
Alexander-Jackson, Eleanor G., 390 Riverside Dr., New York, NY
(New York), US (United States of America), 10025
Livingston, Afton M., 8492 Prestwick Dr., LaJolla, CA
(California), US (United States of America), 92037
[Assignee Code(s): 68000]
EXTRA INFO: Assignment transaction [Reassigned]; recorded July 24,
1990 (19900724)
APPL. NO.: 6-839,457
FILED: March 11, 1986 (19860311)

BACKGROUND OF THE INVENTION

This application is a continuation of U.S. Ser. No. 569,253, filed Jan. 9, 1984, now abandoned; which is a continuation of U.S. Ser. No. 171,543, filed July 23, 1980, now abandoned; which is a continuation of U.S. Ser. No. 955,878, filed Oct. 30, 1978, now abandoned; which is a continuation of U.S. Ser. No. 776,360, filed Mar. 10, 1977, now abandoned; which is a continuation of U.S. Ser. No. 672,965, filed Apr. 2, 1976, now abandoned; which is a continuation of U.S. Ser. No. 295,720, filed Oct. 6, 1972, now abandoned; which is a continuation-in-part of U.S. Ser. No. 082,806, filed Oct. 21, 1970, now abandoned; which is a continuation-in-part of U.S. Ser. No. 831,985, filed June 10, 1969, now abandoned; which is a continuation-in-part of U.S. Ser. No. 490,629 filed Sept. 27, 1965, now

01354207

Utility
PURIFIED HUMAN PROSTATE ANTIGEN

PATENT NO.: 4,446,122
ISSUED: May 01, 1984 (19840501)
INVENTOR(s): Chu, Tsann M., Williamsville, NY (New York), US (United States of America)
Wang, Ming C., Williamsville, NY (New York), US (United States of America)
Papsidero, Lawrence, Lackawanna, NY (New York), US (United States of America)
ASSIGNEE(s): Research Corporation, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 70917]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 27, 1988 (19880527)
Assignment transaction [Reassigned], recorded December 19, 1990 (19901219)
Assignment transaction [Reassigned], recorded March 11, 1991 (19910311)
APPL. NO.: 6-316,954
FILED: August 28, 1981 (19810828)
PCT: PCT-US80-01708 (WO 80US1708)
Section 371 Date: August 28, 1981 (19810828)
Section 102(e) Date: August 28, 1981 (19810828)
Filing Date: December 23, 1980 (19801223)
Publication Number: WO81-01849 (WO 811849)
Publication Date: July 09, 1981 (19810709)

DESCRIPTION OF THE INVENTION

This application is a continuation-in-part of copending, commonly assigned U.S. patent application Ser. No. 108,217 now abandoned, filed Dec.

3/3/49 (Item 45 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02972994

Utility

METHOD TO ELICIT AN ANTITUMOR RESPONSE WITH HUMAN PROSTATE-SPECIFIC ANTIGEN

PATENT NO.: 5,925,362
ISSUED: July 20, 1999 (19990720)
INVENTOR(s): Spitler, Lynn E., Tiburon, CA (California), US (United States of America)
Maida, III, Anthony E., Danville, CA (California), US (United States of America)
ASSIGNEE(s): Jenner Technologies, (A U.S. Company or Corporation), San Ramon, CA (California), US (United States of America)
[Assignee Code(s): 45196]
APPL. NO.: 8-288,057
FILED: August 10, 1994 (19940810)

This is a Continuation-In-Part of U.S. Ser. No. 08-105,444 filed Aug. 11, 1993 now pending. The contents of this application are incorporated herein by reference.

3/3/61 (Item 57 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02842947

Utility
HUMAN CARCINOMA ANTIGEN
[Medical diagnosis; vaccines]

PATENT NO.: 5,808,005
ISSUED: September 15, 1998 (19980915)
INVENTOR(s): Codington, John F., W. Newton, MA (Massachusetts), US (United States of America)
Haavik, Svein, Drobak, NO (Norway)
ASSIGNEE(s): Epigen, Inc , (A U.S. Company or Corporation), Millbrook, NY (New York), US (United States of America)
[Assignee Code(s): 39521]
APPL. NO.: 8-484,061
FILED: June 06, 1995 (19950606)

This is a divisional of application Ser. No. 08-192,840, filed Feb. 7, 1994, now U.S. Pat. No. 5,545,532 which is a continuation-in-part of application Ser. No. 08-014,450, filed Feb. 5, 1993, which is now abandoned.
FULL TEXT: 1143 lines

3/3/62 (Item 58 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02842923

Utility
IMMUNOGENIC PEPTIDES OF PROSTATE SPECIFIC ANTIGEN
[Polypeptide with hydrophilic and hydrophobic regions; cancer diagnosis]

PATENT NO.: 5,807,978
ISSUED: September 15, 1998 (19980915)
INVENTOR(s): Kokolus, William J., 7900 Cambridge St. #14-2L, Houston, TX (Texas), US (United States of America), 77054
Fritsche, Herbert A., 4506 Frontier, Houston, TX (Texas), US (United States of America), 77041
Johnston, Dennis A., 2010 Ramada Dr., Houston, TX (Texas), US (United States of America), 77062
[Assignee Code(s): 68000]
EXTRA INFO: Assignment transaction [Reassigned], recorded August 18, 1995 (19950818)
Assignment transaction [Reassigned], recorded December 14, 1998 (19981214)
APPL. NO.: 8-472,228
FILED: June 07, 1995 (19950607)
FULL TEXT: 1681 lines

3/3/80 (Item 76 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02674861

Utility

METHOD FOR PREPARING LIPOSOMES

[Spraying a solution of amphipathic liposome-forming material, solvent and polypeptide drug through a frequency-generated vibrated atomizing nozzle onto the surface of an aqueous buffer solution; desolventizing]

PATENT NO.: 5,653,996

ISSUED: August 05, 1997 (19970805)

INVENTOR(s): Hsu, Chung C., Los Altos Hills, CA (California), US (United States of America)

ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]

APPL. NO.: 8-407,424

FILED: March 17, 1995 (19950317)

This is a continuation of application Ser. No. 08-084,933 filed on 30 Jun. 1993, now abandoned, which application is incorporated herein by reference and to which application priority is claimed under 35 USC selection 120.

3/3/93 (Item 89 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02099475

Utility

MONOCLONAL ANTIBODY TO NOVEL ANTIGEN ASSOCIATED WITH HUMAN TUMORS
[Antitumor agents]

PATENT NO.: 5,134,075

ISSUED: July 28, 1992 (19920728)

INVENTOR(s): Hellstrom, Karl E., Seattle, WA (Washington), US (United
States of America)
Hellström, Ingegerd, Seattle, WA (Washington), US (United
States of America)
Marquardt, Hans, Mercer Island, WA (Washington), US (United
States of America)
Yoneyama, Yoshitaka, Bellevue, WA (Washington), US (United
States of America)

ASSIGNEE(s): Oncogen Limited Partnership, (A U.S. Company or Corporation)
, Seattle, WA (Washington), US (United States of America)
[Assignee Code(s): 14317]

APPL. NO.: 7-312,640

FILED: February 17, 1989 (19890217)

5/7/2 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.

09262884 97461426

Induction of tissue-specific autoimmune prostatitis with **prostatic acid phosphatase** immunization: implications for immunotherapy of prostate cancer.

Fong L; Ruegg CL; Brockstedt D; Engleman EG; Laus R
Stanford University School of Medicine, CA 94305, USA.

Journal of immunology (UNITED STATES) Oct 1 1997, 159 (7) p3113-7,
ISSN 0022-1767 Journal Code: IFB

Contract/Grant No.: CA71725, CA, NCI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Prostatic acid phosphatase (PAP) is uniquely expressed in prostatic tissue and prostate cancer. In this study, the immunogenicity of PAP was investigated in a male rat model. We show that immunization with recombinant rat or human PAP in CFA leads to a significant Ab response, but does not generate CTL or result in autoimmune prostatitis. In contrast, immunization with recombinant **vaccinia** expressing human PAP, but not rat PAP, generates a CTL response and tissue-specific prostatitis in the absence of detectable PAP-specific Abs. These findings suggest that a cellular immune response to PAP, rather than Abs, mediates destructive autoimmune prostatitis. Thus, xenogeneic forms of PAP are a new tool for the induction of prostate-specific immunity and may prove useful for the immunotherapy of prostate cancer.

5/7/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2000 American Chemical Society. All rts. reserv.

129329394 CA: 129(25)329394e PATENT

A prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

INVENTOR(AUTHOR): Laus, Reiner; Ruegg, Curtis L.; Shapero, Michael H.; Yang, Demao

LOCATION: USA

ASSIGNEE: Dendreon Corp.

PATENT: PCT International ; WO 9846769 A1 DATE: 19981022

APPLICATION: WO 98US7232 (19980410) *US 43301 (19970411)

PAGES: 30 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/55A; C12N-009/16B; C12N-015/86B; A61K-038/46B DESIGNATED COUNTRIES: AU; CA; JP; MX; NO; NZ; US DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB ; GR; IE; IT; LU; MC; NL; PT; SE

SECTION:

CA214001 Mammalian Pathological Biochemistry

CA207XXX Enzymes

CA215XXX Immunochimistry

IDENTIFIERS: mouse prostate acid phosphatase tumor antigen, prostate cancer acid phosphatase antigen vaccine, prostatic acid phosphatase cDNA mouse

DESCRIPTORS:

Genes(animal)...

cDNA, for prostatic acid phosphatase of mouse; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Baculoviridae... Vaccinia virus...

expression vector; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

cDNA sequences...

for prostatic acid phosphatase of mouse; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Protein sequences...

of prostatic acid phosphatase of mouse; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Prostate...

phosphatase of; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Synthetic vaccines...

prostate cancer; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Tumor-associated antigen...

prostatic acid phosphatase as; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Dendritic cell...

pulsed, for vaccination against prostatic acid phosphatase; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

Prostatic tumors...

vaccines against; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

CAS REGISTRY NUMBERS:

214972-44-8 amino acid sequence; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

214972-43-7 nucleotide sequence; prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

9001-77-8 prostatic acid phosphatase from mouse that can be used in vaccines against prostate cancers

5/7/4 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0231366 DBA Accession No.: 99-01467 PATENT

New mouse **prostatic acid phosphatase** - enzyme production

via baculo virus, **vaccinia** virus or adeno virus vector-mediated gene transfer and expression in insect cell culture for use in cancer therapy

AUTHOR: Laus R; Ruegg C L; Shapero M H; Yang D

CORPORATE SOURCE: Mountain View, CA, USA.

PATENT ASSIGNEE: Dendreon 1998

PATENT NUMBER: WO 9846769 PATENT DATE: 981022 WPI ACCESSION NO.:

99-009335 (9901)

PRIORITY APPLIC. NO.: US 43301 APPLIC. DATE: 970411

NATIONAL APPLIC. NO.: WO 98US7252 APPLIC. DATE: 980410

LANGUAGE: English

ABSTRACT: An isolated protein with equal to or more than 90% identity to mouse **prostatic acid phosphatase** (mPAP, EC-3.1.3.2, cloned via polymerase chain reaction), with a specified amino acid, is new. Also claimed are: an isolated polynucleotide (II) encoding (I); and an expression vector (baculo virus in an insect cell expression system) containing (II) and regulatory elements for (II) expression. (I) may be used for inducing an immune response against a tumor-associated antigen (preferably human PAP), by administering a composition of a xenogeneic form of a tumor-related antigen from a different mammalian sp., i.e. (I). (I) may also be used in an antigen composition including a dendritic cell pulsed in vitro with (I) and recombinant viruses expressing (I) may be used in compositions to elicit immune response against a tumor-related antigen. Immunization with xenogeneic forms of recombinant PAP leads to the formation of cross-reactive antibodies which react with autologous form of PAP. The composition may also be useful for reducing the tumor cell load. (I) can also be expressed in a viral expression system, e.g. **vaccinia** virus, adeno or adeno-like virus. (28pp)